Introduction
Increasingly across the world, first-trimester screening is becoming the standard-of-care method for prenatal aneuploidy screening. In large cohorts, combined first-trimester nuchal translucency (NT) and serum analyte measurements can detect approximately 80-85% of fetuses affected by Down syndrome, a detection rate that is similar to that of second-trimester analyte screening. 1, 2 Despite recommendation by the American College of Obstetricians and Gynecologists and other medical societies to universally offer first trimester screening, 3 some states have yet to incorporate first-trimester screens into government-funded aneuploidy screening programs.
In March 2009, the California State Genetic Disease Branch introduced a state-wide integrated first-and second-trimester aneuploidy screening program. Through this program, Medi-Cal (state insured) patients who previously only had access to state-sponsored second-trimester analyte screening were now eligible for first-trimester NT measurement plus serum analyte screen, second-trimester serum analyte screen, integrated firstand second-trimester serum analyte only screen or integrated complete first-and second-trimester aneuploidy screen (NT plus first-and second-trimester serum analytes).
Little data exist with regard to the potential effects of such programs on individual prenatal diagnostic centers, specifically the resources necessary to accommodate the potential increase in the volume of patients presenting for prenatal screening and/or diagnostic procedures. The objective of our study was to assess the effect of greater patient access to prenatal screening on available resources at a single academic center.
Methods
We conducted a review of prenatal screening and diagnostic testing performed at a single academic center, Lucile Salter Packard Children's Hospital at Stanford University. Patients interested in prenatal screening and/or diagnostic testing are routinely referred to either our main Perinatal Diagnostic Center (PDC) or to one of our four affiliated regional satellite offices. Each office has dedicated genetic counselors and daily coverage by a perinatologist and sonographers. Patients undergoing first-trimester screening are eligible for prenatal diagnostic (amniocentesis and chorionic villus sampling (CVS)) testing if desired, and each office is dedicated solely to obstetrical imaging, prenatal testing and perinatal consultation. Patients undergoing NT screening undergo counseling by the referring provider before arrival at our PDC. Occasionally, some patients are also referred for genetic counseling before NT measurement at the provider's discretion in order to review the aneuploidy screening and diagnostic testing options available.
According to the California Genetic Disease Branch, firsttrimester analyte screening is offered to women between 10 0/7 and 13 6/7 weeks gestational age, and NT measurements can be obtained with a fetal crown-rump length between 45 and 84. analyzed using SAS 9.1 (SAS, Cary, NC, USA) and Stata 11.0 (Stata Corp, College Station, TX, USA). The mean number of procedures performed per month was compared before and after the transition using Student's t-test. We considered a P-value of <0.05 to be statistically significant. The 'after' period was also divided into 4-month intervals, and the mean number of procedures by interval was compared with analysis of variance, using Tukey's method of multiple comparisons.
We also examined whether the indication for performing CVS and amniocentesis had changed over time during the study period. Linear trends in the proportion of procedures performed were tested using generalized linear models with a binomial link function, with month of procedure considered as a continuous variable. The study period for this analysis included the 16-month period from 1 December 2008 to 31 March 2010. The indications for testing included the following: positive aneuploidy screen, maternal age greater than 35 at delivery and other indications including abnormal ultrasound findings and family history of aneuploidy. The proportion of each reason was evaluated for both CVS and amniocentesis.
The study was approved by the Stanford Institutional Review Board. (Table 1) . 
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This increase in average monthly NT procedures performed was not associated with a significantly greater number of average monthly CVS (24 vs 26, P ¼ 0.46) or amniocentesis procedures (90 vs 79, P ¼ 0.18) performed for all indications. In our center, the majority of invasive procedures, both amniocentesis and CVS, were still performed for the indication of advanced maternal age followed by the indication of positive screening results (Figures 4 and 5) .
When analyzing the linear trends, a greater proportion of amniocentesis procedures were performed for positive screens (P ¼ 0.002) and fewer were performed for advanced maternal age (P ¼ 0.009). There was a similar relationship for CVS with an increase in the proportion of procedures performed for positive screens (P ¼ 0.008) and a decrease in the proportion performed for maternal age (P ¼ 0.013). None of the other indications had significant changes during the study period.
Discussion
The introduction of the California prenatal screening program markedly increased the number of NT procedures performed at our academic center and affiliated satellite clinics. This was not associated with an increase in overall CVS or amniocentesis procedures for all indications, although larger studies are required to assess this effect over a longer period of time. Importantly, when assessed by indication, there was an increase in the proportion of amniocentesis procedures that were performed for positive screening and a decrease in amniocentesis procedures that were performed for advanced maternal age. However, the majority of procedures were still performed for advanced maternal age, even at the end of the study period.
In 2007, the American College of Obstetricians and Gynecologists published a Practice Bulletin titled Invasive Prenatal Testing for Aneuploidy. 3 In this paper, American College of Obstetricians and Gynecologists officially recognized the shift in fetal aneuploidy screening and diagnosis to the first trimester and advocated that invasive diagnostic testing, including CVS, become 'available to all women' regardless of a priori risk factors including advanced maternal age. Increasingly, first-trimester screening has become the gold-standard method of prenatal aneuploidy screening. Organizations such as the Society for Maternal-Fetal Medicine, (http://www.smfm.org) the Nuchal Translucency Quality Review Program (http://www.ntqr.org) and the Fetal Medicine Foundation (http://www.fetalmedicine.com) routinely educate, certify and monitor the performance of fetal ultrasound NT measurements by obstetrician-gynecologists, maternal-fetal medicine sub-specialists and other prenatal-care providers.
Despite the increased number of first-trimester aneuploidy screens performed, the number of CVS procedures performed during the study period remained largely unchanged. This finding may be explained by several factors. First of all, it is possible that many women with first-trimester screen-positive results elected to Utilization of prenatal screens and diagnosis YJ Blumenfeld et al proceed with integrated second-trimester screening before deciding to undergo definitive diagnostic testing. Second, it is possible that a regional bias exists against CVS compared with amniocentesis, both by patients and providers. This is contrary to newer data suggesting equal safety profiles between the two procedures, 4,5 especially with experienced providers.
Our finding of decreasing amniocentesis and CVS solely for advanced maternal age is consistent with prior studies. A recent study by Nakata et al. evaluated 163 756 patients referred to Genzyme Genetics for genetic counseling because of advanced maternal age, from 2001 to 2008. 6 During this period, firsttrimester screening increased from 45 to 85%; however, the authors found a decrease in amniocentesis from 56 to 31% and in CVS from 36 to 14% over the same period. The effect of large systemwide prenatal screening programs was also described by Ekelund et al. 7 In their study detailing the effect of the Danish Prenatal Screening Program, the authors described a decrease in the number of prenatal diagnostic procedures performed (4202 to 1208 amniocentesis and 3322 to 2302 CVS procedures) from 2000 to 2006 while the uptake in prenatal screening reached 84% over the same period.
Data from international large-scale prenatal screening programs also highlight another important fact that utilization of prenatal screening and diagnostic testing depends largely on patient ethnic and religious background, as well as preconceived notions of genetic abnormalities. 8, 9 Moreover, ethnic and socioeconomic factors have been shown to affect the perceived risk of carrying a Down syndrome-affected fetus or having a procedurerelated miscarriage. 10, 11 The effects of ethnic background and socioeconomic factors on uptake of prenatal diagnostic testing among Medi-Cal women are still unclear. Regardless, states contemplating launching large-scale prenatal screening programs should evaluate their local populations to forecast the number of providers needed for both prenatal screening and diagnostic testing.
Our study is not without limitations. First, our findings may be limited by a relatively short follow-up period. It is conceivable that future data will reveal different findings over time, especially with regard to the uptake of available invasive diagnostic testing. In addition, it is possible that the increase in NT procedures performed in our center is the result of increased awareness and acceptance of NT screening in our community, rather than a direct result of state-wide implementation of the screening program. On the other hand, our center has been performing first-trimester screening since 2004, allowing ample opportunity for our referring providers to accept this modality for patients with private insurance. Finally, our findings need to be taken with caution, as they are mainly applicable to centers such as ours who provide care to both MediCal and private insurance patients.
Overall, our data suggest that individual prenatal diagnostic centers participating in the California aneuploidy screen program may need to accommodate a greater number of women presenting for first-trimester screening. More data are needed to assess whether the number of NT providers in the state of California can meet this demand. In addition, if California is to become a national model, prenatal centers contemplating participating in large governmentfunded screening programs may need to accommodate more women presenting for first-trimester screening. Finally, more data are needed to assess trends in invasive diagnostic procedures, and to assure that adequate resources are available to patients should they desire definitive prenatal diagnostic testing.
